CA-ALATION
New research from Alation Inc. , the leader in enterprise data intelligence solutions, reveals that the C-suite is dangerously behind in making needed investments in data and analytics. According to the latest Alation State of Data Culture Report , only 18% of data leaders expect to receive the full amount of funding they say is necessary to get or stay ahead of the competition for data and analytics, even as almost all (98%) cite needing it.
Data leaders feel the pressure to remain competitive and the Alation State of Data Culture Report has repeatedly shown a direct correlation between a strong data culture and an organisation’s ability to achieve or exceed revenue goals. More than 600 data leaders globally participated in this research study and the latest report found that organisations with a top-tier data culture remain the most likely to meet or exceed their revenue goals, as almost all (90%) did so over the past 12 months. Yet, 66% of data leaders cite company leadership as an obstacle to getting the funding they need, including 42% who say the C-suite doesn’t follow through on promised investment in programs that drive data culture.
In addition, only 29% of data leaders are very confident that their CEO understands the link between investment in data and analytics and staying ahead of the competition. This points to a strategy gap where C-level executives pay lip service to the benefits of investing in data and analytics, but don’t make it a priority, leaving organisations vulnerable to disruption.
“As awareness about data culture grows, executives and their organisations are learning how hard it is to build a solid foundation for it. Early in the life cycle of this research many either thought they were done or barely acknowledged the problem, whereas today, executives know they have a bigger hill to climb. There’s a lack of funding dedicated to creating a data culture that drives revenue and operational efficiency,” said Satyen Sangani, co-founder and CEO, Alation. “If these organisations fail to recognise the power of data-driven decision making, and don’t fund data and analytics initiatives properly, at best they’ll introduce significant risk to their organisations; at worst, be disrupted by competitors that threaten their existence.”
The Data Catalog Remains at the Heart of Establishing Data Culture
Data leaders have identified several core areas for investment to improve their organisation’s data culture, with 87% of data leaders agreeing that data catalogs are very important or essential to their efforts. This is a significant increase from 68% of data leaders in Q3 2021
, just 6 months earlier. Respondents also agree the first steps to building a data culture include creating data processes (44%), creating an inventory of existing data (43%), and fixing existing data quality
issues (38%).
Produced by Wakefield Research for Alation, the report includes the Alation Data Culture Index™ (DCI), a quantitative assessment of how well an organisation is positioned to enable data-driven decision-making across three key disciplines: data search & discovery, data literacy, and data governance. Enterprises are ranked low-, mid-, and top-tier based on how widely adopted these disciplines are across the enterprise.
For more information, download the Q1 2022 Alation State of Data Culture Report and read the blog, The Data Culture Gap : Q1 2022 State of Data Culture Report.
About the Alation State of Data Culture Report
The Alation State of Data Culture Report is a study sponsored by Alation and executed by Wakefield Research. Wakefield Research conducted a quantitative research study among 620 Data & Analytics Leaders at enterprises with 2,500+ employees in 14 markets across the US, EMEA, and APAC regions, with a minimum title requirement of Senior Director. Enterprises are polled annually regarding the progress of establishing a data culture — i.e., a culture of data-driven decision making — within their organisations, the challenges they face in embracing data-driven decision making, and the progress they have made in leveraging data to drive business value for their organisation.
About Alation
Alation is the leader in enterprise data intelligence solutions including data search & discovery, data governance, data stewardship, analytics, and digital transformation. Alation’s initial offering dominates the data catalog market. Thanks to its powerful Behavioral Analysis Engine, inbuilt collaboration capabilities, and open interfaces, Alation combines machine learning with human insight to successfully tackle even the most demanding challenges in data and metadata management. More than 330 enterprises drive data culture, improve decision making, and realise business outcomes with Alation including AbbVie, American Family Insurance, Cisco, Exelon, Fifth Third Bank, Finnair, Munich Re, NASDAQ, New Balance, Parexel, Pfizer, US Foods, and Vistaprint. Headquartered in Silicon Valley, Alation was named to Inc. Magazine’s Best Workplaces list and is backed by leading venture capitalists including Blackstone, Costanoa, Data Collective, Dell Technologies, Icon, ISAI Cap, Riverwood, Salesforce, Sanabil, Sapphire, and Snowflake Ventures. For more information, visit alation.com
.
About Wakefield Research
Wakefield Research supports the world’s most prominent brands and agencies, including 50 of the Fortune 100, in 90 countries. We provide quantitative, qualitative, and hybrid market research and market intelligence. Our work is regularly featured in the media.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220427005221/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release
Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release
MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
